National Pharmaceutical Regulatory Agency (NPRA) (NPRA)
National Pharmaceutical Regulatory Agency (NPRA) is the official source of medicine shortage information for Malaysia (Asia Pacific). Mederti checks its register daily and links every notice back to the original publication.
- Official register
- www.npra.gov.my
- Country
- Malaysia
- Notices tracked by Mederti
- 230
- Last checked
- 2 Aug 2026
Latest notices from NPRA
- Cefazolin — active, medium, since 1 Jan 2026 (source)
- Vitamin D3 — active, medium, since 1 Jan 2026 (source)
- Mesalazine — active, medium, since 1 Jan 2026 (source)
- Moxifloxacin Drug Reaction — active, medium, since 1 Jan 2026 (source)
- Denosumab Prolia — active, medium, since 1 Jan 2026 (source)
- Clindamycin Hydrochloride Oral Capsules — active, medium, since 1 Jan 2026 (source)
- Vitamin B6 Pyridoxine — active, medium, since 1 Jan 2026 (source)
- Prescription Opioid — active, medium, since 1 Jan 2026 (source)
- Garcinia Cambogia (2015 — active, medium, since 1 Jan 2026 (source)
- Garcinia Cambogia — active, medium, since 1 Jan 2026 (source)
- Palbociclib — active, medium, since 1 Jan 2026 (source)
- Linezolid — active, medium, since 1 Jan 2026 (source)
- Sunitinib — active, medium, since 1 Jan 2026 (source)
- Denosumab — active, medium, since 1 Jan 2026 (source)
- Aciclovir Brill Pharma — active, medium, since 1 Jan 2026 (source)
Every NPRA notice, searchable and alertable
Search Malaysia's full register alongside 50+ other countries — free for individual pharmacists and clinicians.
Create a free accountMederti is not affiliated with or endorsed by National Pharmaceutical Regulatory Agency (NPRA). All notices remain the property of their publisher and are linked to the original source.